表紙
市場調査レポート

術後疼痛:パイプライン製品の分析

Post-Operative Pain - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 227536
出版日 ページ情報 英文 187 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
術後疼痛:パイプライン製品の分析 Post-Operative Pain - Pipeline Review, H2 2016
出版日: 2016年07月13日 ページ情報: 英文 187 Pages
概要

疼痛は、術後の患者にストレスを感じさせる主な有害事象の一つです。疾病素質には年齢や、恐怖・不安のレベル、外科手術工程、個人的な選考、投与された薬剤への反応などが挙げられます。主な治療薬には、鎮痛剤や麻酔薬などがあります。

当レポートでは、世界各国での術後疼痛治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

術後疼痛の概要

治療薬の開発

  • 術後疼痛向けパイプライン製品:概要
  • 術後疼痛向けパイプライン製品:比較分析

各企業で開発中の術後疼痛治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

術後疼痛治療薬:開発中の製品の一覧(企業別)

術後疼痛治療薬の開発に従事している企業

  • AcelRx Pharmaceuticals, Inc.
  • Adynxx, Inc.
  • AngioChem Inc.
  • AskAt Inc.
  • Boehringer Ingelheim GmbH
  • Cara Therapeutics, Inc.
  • Colby Pharmaceutical Company
  • Cytogel Pharma, LLC
  • Dompe Farmaceutici S.p.A.
  • DURECT Corporation
  • Echo Pharmaceuticals B.V.
  • 藤本製薬
  • Galleon Pharmaceuticals
  • Grunenthal GmbH
  • GW Pharmaceuticals Plc
  • Heron Therapeutics, Inc.
  • Immupharma Plc
  • Innocoll AG
  • INSYS Therapeutics, Inc.
  • Laboratorios Del Dr. Esteve S.A.
  • Lipocure Ltd.
  • Liquidia Technologies, Inc.
  • Medtronic plc
  • Orbis Biosciences, Inc.
  • Orion Oyj
  • Pacira Pharmaceuticals, Inc.
  • PainReform Ltd.
  • Pharmazz, Inc.
  • PhytoHealth Corporation
  • Proteus SA
  • Recro Pharma, Inc.
  • Relmada Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SteadyMed Therapeutics, Inc.
  • 武田薬品工業
  • The Medicines Company
  • Trevena, Inc.

術後疼痛:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

術後疼痛治療薬:開発が休止状態の製品

術後疼痛治療薬:開発が中止された製品

術後疼痛関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8219IDB

Summary

Global Markets Direct's, 'Post-Operative Pain - Pipeline Review, H2 2016', provides an overview of the Post-Operative Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
  • The report reviews pipeline therapeutics for Post-Operative Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Post-Operative Pain therapeutics and enlists all their major and minor projects
  • The report assesses Post-Operative Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Post-Operative Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Post-Operative Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post-Operative Pain Overview
  • Therapeutics Development
    • Pipeline Products for Post-Operative Pain - Overview
  • Post-Operative Pain - Therapeutics under Development by Companies
  • Post-Operative Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Post-Operative Pain - Products under Development by Companies
  • Post-Operative Pain - Companies Involved in Therapeutics Development
    • AcelRx Pharmaceuticals, Inc.
    • Adynxx, Inc.
    • AngioChem Inc.
    • AskAt Inc.
    • Boehringer Ingelheim GmbH
    • Cara Therapeutics, Inc.
    • Colby Pharmaceutical Company
    • Cytogel Pharma, LLC
    • Dompe Farmaceutici S.p.A.
    • DURECT Corporation
    • Echo Pharmaceuticals B.V.
    • Fujimoto Pharmaceutical Corporation
    • Galleon Pharmaceuticals
    • Grunenthal GmbH
    • GW Pharmaceuticals Plc
    • Heron Therapeutics, Inc.
    • Immupharma Plc
    • Innocoll AG
    • INSYS Therapeutics, Inc.
    • Laboratorios Del Dr. Esteve S.A.
    • Lipocure Ltd.
    • Liquidia Technologies, Inc.
    • Medtronic plc
    • Orbis Biosciences, Inc.
    • Orion Oyj
    • Pacira Pharmaceuticals, Inc.
    • PainReform Ltd.
    • Pharmazz, Inc.
    • PhytoHealth Corporation
    • Proteus SA
    • Recro Pharma, Inc.
    • Relmada Therapeutics, Inc.
    • Serina Therapeutics, Inc.
    • SteadyMed Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • The Medicines Company
    • Trevena, Inc.
  • Post-Operative Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (bupivacaine hydrochloride + meloxicam) - Drug Profile
    • AM-4 - Drug Profile
    • ANG-2002 - Drug Profile
    • ARX-04 - Drug Profile
    • AYX-1 - Drug Profile
    • BI-1026706 - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride - Drug Profile
    • bupivacaine hydrochloride ER - Drug Profile
    • bupivacaine hydrochloride SR - Drug Profile
    • buprenorphine hydrochloride - Drug Profile
    • CPC-123 - Drug Profile
    • CR-4056 - Drug Profile
    • Cyt-1010 - Drug Profile
    • dexmedetomidine hydrochloride - Drug Profile
    • DF-2755A - Drug Profile
    • difelikefalin - Drug Profile
    • difluprednate XR - Drug Profile
    • dronabinol - Drug Profile
    • Drug for Post Operative Pain - Drug Profile
    • ECP-1014 - Drug Profile
    • fadolmidine hydrochloride - Drug Profile
    • fentanyl - Drug Profile
    • GAL-044 - Drug Profile
    • grapiprant - Drug Profile
    • IPP-102199 - Drug Profile
    • ketamine hydrochloride - Drug Profile
    • ketorolac tromethamine - Drug Profile
    • levorphanol tartrate ER - Drug Profile
    • MDT-10013 - Drug Profile
    • meloxicam - Drug Profile
    • meloxicam ER - Drug Profile
    • meloxicam ER - Drug Profile
    • MR-309 - Drug Profile
    • nabiximols - Drug Profile
    • nalbuphine hydrochloride - Drug Profile
    • neosaxitoxin - Drug Profile
    • oliceridine - Drug Profile
    • PMZ-2010 - Drug Profile
    • RBM-004 - Drug Profile
    • ropivacaine - Drug Profile
    • ropivacaine ER - Drug Profile
    • SER-226 - Drug Profile
    • Small Molecule for Post-Operative Pain - Drug Profile
    • sufentanil citrate - Drug Profile
    • tapentadol hydrochloride - Drug Profile
    • tramadol hydrochloride - Drug Profile
    • tramadol hydrochloride ER - Drug Profile
    • URB-937 - Drug Profile
    • VVZ-149 - Drug Profile
  • Post-Operative Pain - Dormant Projects
  • Post-Operative Pain - Discontinued Products
  • Post-Operative Pain - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Post-Operative Pain, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Adynxx, Inc., H2 2016
  • Post-Operative Pain - Pipeline by AngioChem Inc., H2 2016
  • Post-Operative Pain - Pipeline by AskAt Inc., H2 2016
  • Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Post-Operative Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Colby Pharmaceutical Company, H2 2016
  • Post-Operative Pain - Pipeline by Cytogel Pharma, LLC, H2 2016
  • Post-Operative Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Post-Operative Pain - Pipeline by DURECT Corporation, H2 2016
  • Post-Operative Pain - Pipeline by Echo Pharmaceuticals B.V., H2 2016
  • Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corporation, H2 2016
  • Post-Operative Pain - Pipeline by Galleon Pharmaceuticals, H2 2016
  • Post-Operative Pain - Pipeline by Grunenthal GmbH, H2 2016
  • Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Post-Operative Pain - Pipeline by Heron Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Immupharma Plc, H2 2016
  • Post-Operative Pain - Pipeline by Innocoll AG, H2 2016
  • Post-Operative Pain - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
  • Post-Operative Pain - Pipeline by Lipocure Ltd., H2 2016
  • Post-Operative Pain - Pipeline by Liquidia Technologies, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Medtronic plc, H2 2016
  • Post-Operative Pain - Pipeline by Orbis Biosciences, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Orion Oyj, H2 2016
  • Post-Operative Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016
  • Post-Operative Pain - Pipeline by PainReform Ltd., H2 2016
  • Post-Operative Pain - Pipeline by Pharmazz, Inc., H2 2016
  • Post-Operative Pain - Pipeline by PhytoHealth Corporation, H2 2016
  • Post-Operative Pain - Pipeline by Proteus SA, H2 2016
  • Post-Operative Pain - Pipeline by Recro Pharma, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Relmada Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Serina Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by SteadyMed Therapeutics, Inc., H2 2016
  • Post-Operative Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Post-Operative Pain - Pipeline by The Medicines Company, H2 2016
  • Post-Operative Pain - Pipeline by Trevena, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Post-Operative Pain - Dormant Projects, H2 2016
  • Post-Operative Pain - Dormant Projects (Contd..1), H2 2016
  • Post-Operative Pain - Dormant Projects (Contd..2), H2 2016
  • Post-Operative Pain - Dormant Projects (Contd..3), H2 2016
  • Post-Operative Pain - Dormant Projects (Contd..4), H2 2016
  • Post-Operative Pain - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Post-Operative Pain, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top